Latest Immunitor Inc. Stories
Immunitor Inc., reported that company’s first proof-of-concept clinical study of its candidate cancer vaccine in patients with terminal stage of liver cancer has been presented at the immunology
Presentation details three separate tuberculosis immunotherapies developed by Immunitor in collaboration with academic institutions and private companies in Mongolia, China, Thailand, Ukraine,
Immunitor, Inc., a commercial stage company committed to developing oral therapeutic vaccines, today announced that its second Phase II trial of oral TB vaccine with heat-killed Mycobacterium
- A volcanic mudflow.